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Abstract
Apolipoprotein B (apoB) containing lipoproteins, i.e. VLDL, LDL and Lp(a), are consequently lowered by ACTH treatment 
in humans. This is also seen as reduced plasma apoB by 20-30% and total cholesterol by 30-40%, mostly accounted for 
by a decrease in LDL-cholesterol. Studies in hepatic cell line (HepG2) cells showed that apoB mRNA expression is 
reduced in response to ACTH incubation and is followed by a reduced apoB secretion, which may hypothesize that 
ACTH lowering apoB containing lipoproteins in humans may be mediated by the inhibition of hepatic apoB synthesis. 
This was recently confirmed in vivo in a human postprandial study, where ACTH reduced transient apoB48 elevation 
from the small intestine, however, the exogenic lipid turnover seemed unimpaired. In the present study we 
investigated if lipid synthesis and/or secretion in HepG2 cells were also affected by pharmacological levels of ACTH to 
accompany the reduced apoB output. HepG2 cells were incubated with radiolabelled precursors ([14C]acetate and 
[3H]glycerol) either before or during ACTH stimuli. Cellular and secreted lipids were extracted with 
chloroform:methanol and separated by the thin layer chromatography (TLC), and [14C]labelled cholesterol and 
cholesteryl ester and [3H]labelled triglycerides and phospholipids were quantitated by the liquid scintillation counting. 
It demonstrated that ACTH administration did not result in any significant change in neither synthesis nor secretion of 
the studied lipids, this regardless of presence or absence of oleic acid, which is known to stabilize apoB and enhance 
apoB production. The present study suggests that ACTH lowers plasma lipids in humans mainly mediated by the 
inhibition of apoB synthesis and did not via the reduced lipid synthesis.
Introduction
ACTH (adrenocorticotrophic hormone) is primary
involved in the regulation of steroid hormone synthesis in
the adrenal gland [1,2]. When ACTH is administered
exogenous it has proven to have positive function on neu-
rological diseases such as infantile spasms and multiple
sclerosis [3,4]. Over the last decade we have demon-
strated that ACTH also has beneficial effects on lipid pro-
file that is not accounted for by the induction of steroid
hormone synthesis. ACTH systematically lowers all lipo-
proteins containing apolipoprotein (apo) B, i.e. very low-
density lipoprotein (VLDL), low-density lipoprotein
(LDL) and Lipoprotein (a), while high-density lipoprotein
(HDL) rather is elevated [5]. Further a pronounced and
consistent decrease of plasma total cholesterol in particu-
lar LDL-cholesterol by 30-40% is seen after ACTH treat-
ment in healthy individuals and in patients with
secondary hyperlipidemia [5-9]. Plasma phospholipids
are also significantly reduced and triglycerides are mainly
lowered, especially in patients with initially high levels
[5,6,8-10].
Studies in vitro, in the HepG2 cell line, indicated that
output of apoB and not elimination of apoB containing
lipoproteins, via the liver, was the effect of ACTH. Thus,
at 10 times physiological level, ACTH significantly and
selectively suppresses apoB mRNA levels and apoB secre-
tion, while the receptor mediated uptake of apoB contain-
ing lipoproteins, via the LDL receptor or scavenger
receptor-BI, or the mRNAs of these receptors were
unchanged [11]. The hypothesis that ACTH reduced
apoB output was further supported in vivo, by using the
human postprandial phase to study the induced apoB48
production. In healthy humans ACTH significantly
inhibited the transient rise in apoB48 in plasma, while the
lipid handling, followed as triglycerides and retinyl palmi-
tate, seemed unimpaired [10]. We hypothesised that
ACTH induced the intestinal cells to produce larger,
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more lipid rich, but fewer lipoproteins. To see if this is the
case also in hepatic cells we herein studied the effects of
ACTH on lipid handling i.e. synthesis and secretion in
liver cell cultures where we know apoB output is reduced
in response to ACTH.
Materials and methods
Materials
RPMI 1640 with L-glutamine, fetal calf serum (FCS), pen-
icillin/streptomycin (10000 units/mL/10000 μg/mL) and
trypsin-EDTA were obtained from Life Technologies.
The hepatoblastoma cell line HepG2 was obtained from
the American Type Culture Collection, Manassas, VA.
Vented cell culture flasks, 25-cm2 were from Nunc, Den-
mark. ACTH1-39 (porcine pituitary), oleic acid (OA),
human serum albumin (HSA) and bovine serum albumin
(BSA) were from Sigma. ACTH1-24 (Synacthen) was
from Novartis and Insulin (Actrapid) was from Novo
Nordisk. [1-14C]acetate (acetic acid-sodium salt, specific
activity 57,0 mCi/mmol) and [2-3H]glycerol (specific
activity 1 Ci/mmol) was from Amersham Pharmacia Bio-
tech and scintillation liquid (OptiFluor) was from Perkin
Elmer. Thin layer chromatograph plates, aluminium
sheets with silica gel 60, were from Merck. Internal stan-
dards cholesterol, cholesteryl oleate, phosphatidylcho-
line and glyceryl trioleate was from Sigma. All other
chemicals and solvents used were of analytical grade.
Cell culture conditions
Stock cultures of HepG2 were kept in 25-cm2 flasks under
basal conditions. RPMI 1640 complemented with 100
units/mL penicillin and 100 μg/mL streptomycin and
standard culture conditions (5%CO2, 37°C), with 10%
FCS present. Medium was changed every second to third
day. Cells were subcultured every seventh day, just prior
to reaching confluence, into new stock culture and to
experimental cultures. Cells were only used up to 20-25
subcultures and were regular controlled for mycoplasma
presence. Into each experimental flask (25 cm2) 3 ×
105cells/mL were seeded. Medium was changed every
second to third day and between incubations with differ-
ent experimental media cells were washed twice with
phosphate-buffered saline (PBS). During all the experi-
ments cells were subconfluent and all experimental
media contained penicillin/streptomycin and FCS was
substituted with 0,5% HSA. Basal experimental media
contained 0,4 mM oleic acid if not mentioned otherwise.
Oleic acid is suggested to increase stability of apoB and
hence increase synthesis of apoB containing lipoproteins
[12]. Briefly, oleic acid (dried under nitrogen) and HSA
(water solution), molar ratio 20:1, was strongly vortexed
and was inversed over night at 8°C. The suspension was
added to experimental media, containing 0,5% HSA, to
obtain the final ratio 4:1 of oleic acid and HSA.
Assay of lipid synthesis and secretion
Prelabel studies; HepG2 cells were incubated in experi-
mental medium with radionuclides, [14C]acetate (0,5 μCi/
ml) or [3H]glycerol (1 μCi/ml) for 20 hrs. Medium was
replaced with experimental medium containing ACTH
(10, 100 or 200 pM Synacthen1-24) or insulin (1 mg/ml
(170 mM) Actrapid). Continuous labelling; HepG2 cells
were preconditioned in the experimental medium with
ACTH (100 pM ACTH1-39) for 24 hrs. Medium was
replaced with experimental medium containing ACTH
and [14C]Acetate (0,5 μCi/ml) or [3H]Glycerol (1 μCi/ml).
During time media samples were collected and stored at -
20°C. After 24 hrs cells were scraped into 1 mL of PBS.
Extraction and analysis of lipids
Lipids were extracted from cell and media samples with
[chloroform: methanol (1:2; v/v)] [13]. Briefly, step 1: Add
[chloroform: methanol (1:2)] to obtain ratio 1:2:1 of [chlo-
roform: methanol: water (sample and KH2PO4, 0,1 M, pH
7,45)]. Remove upper phase of water-soluble products.
Step 2: Add chloroform and KH2PO4 to obtain ratio 2:1:1
of [chloroform: methanol: water]. Remove upper phase
and wash lipid phase with equal volume of [chloroform:
methanol: KH2PO4 (30:480:470)]. The lipid phase was
dried under nitrogen gas, dissolved in a small volume of
chloroform together with internal standards of unlabeled
lipids (cholesterol, cholesteryl oleate, phosphatidylcho-
line and glyceryl trioleate). The samples were applied
onto the TLC plates that were preactivated at 80°C over
night. Lipids were separated in [petroleumether: diethyl
ether: acetic acid (75:25:1; v/v)] for 45 min [14], and were
visualised by iodine vapour. The spots were solved in 1
mL of methanol: water (1:1; v/v) and counted in 10 mL of
scintillation liquid (OptiFluor) in a beta counter (Rack
beta 1214).
Recovery of [14C] radioactivity with prelabel design
After 20 hrs incubation with radioisotope the intracellu-
lar activity comprised 40% of the added activity. Of this
cellular activity 83% is organically solved and after a 24
hrs chase period 81% is recovered from cells and media as
cholesterol, cholesteryl ester, phospholipids, triglycerides
and free fatty acids as separated by the TLC.
Analysis of total protein
Total protein contents of cells were measured according
to Lowry [15] with BSA as standard. Cells in PBS were
lysed with addition of equal volume of NaOH (0,1 M).
Protein content of cells did not differ between treated and
untreated cells.
Statistical analysis
Results are expressed as mean ± SD. Data were statistical
analysed with GraphPad Prism software. ANOVA wasSkoog et al. Lipids in Health and Disease 2010, 9:48
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used for comparisons of three groups with Bonferroni
post-test for selected pairs of columns. Significant differ-
ence was established at p < 0.05.
Results
Cells prelabelled with radionuclides were stimulated with
ACTH (10, 100 or 200 pM) for 24 hrs and lipids were
assessed in media and harvested cells. In the cells the
lipid pools of de novo synthesised cholesterol, cholesteryl
ester, triglycerides and phospholipids, from the radionu-
clide precursors, were not affected by the ACTH (Fig.
1A), and there was no difference between the groups pre-
treated by different ACTH concentrations (data not
shown). Secretion of synthesised radiolabelled lipids at 24
hrs was also unaffected by the ACTH (Fig. 1B). Cells
incubated with insulin as a positive control [16] showed a
strong significant reduction of secreted lipids at 24 hrs,
although the cellular pool was not changed. Over the 24-
hour chase period, after prelabelling, the total output of
labelled products into media was increasing, measured as
total [14C] decays in the media (Fig. 1C). ACTH incuba-
tion did not alter the output of labelled products, while
incubation with insulin showed a significant divergence
of de novo labelled material in the media already at 6 hrs.
When HepG2 cells had continuous access to lipid pre-
cursor, de novo synthesised and secreted lipids are accu-
mulated over time in the media (Fig. 2A-D). The presence
of ACTH had no effect on secretion of the radiolabelled
lipids, cholesterol, cholesteryl ester, triglycerides and
phospholipids, at any time-point even though the cells
had been prestimulated with ACTH for 24 hrs as well. In
separate experiments under identical conditions, handled
in parallel with cells for lipid studies, ACTH reduced
apoB mRNA as seen previously (data not shown), this
ensured us that the HepG2 cells was responsive to
ACTH. Similar to the accumulation of de novo synthe-
sised and secreted lipids with continuous labelling were
seen with prelabel design and also then there were no
effect of ACTH (Data not shown). Cells allowed to run in
experimental medium for 48 hrs (prelabel or continuous
label) show almost no further accumulation of labelled
lipids in media at 48 hrs compared to 24 hrs regardless of
presence of ACTH (Data not shown).
Lipid contents in cells and media have further been
studied at 4 and 16 hrs of ACTH stimulation. There was
no obvious effect of ACTH on cellular or secreted
labelled lipids at these times intervals as well (Data not
shown). Oleic acid was used in the experimental medium
Figure 1 Contents of labelled lipids in cells and culture media. HepG2 cells prelabelled with [14C]acetate or [3H]glycerol was incubated with ACTH 
(200 pM Synacthen) and insulin (1 mg/ml actrapid). Labelled cholesterol, cholesteryl ester, triglyceride and phospholipid, respectively, were evaluated 
after 24 hrs in cells (A) and media (B). Total secretion of [14C] products was followed during the experiment (C). Data represent mean ± SD of two re-
peated experiments (N = 11). ** p < 0,01, *** p < 0,001.
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since it is known to increase stability of apoB and hence
increase synthesis of apoB containing lipoproteins [12].
When oleic acid was excluded from the experimental
medium there was a change in output of radiolabelled lip-
ids in cells and media, as expected. However, ACTH did
not change synthesis or secretion of labelled lipids in the
absence of oleic acid either (Fig. 3A and 3B).
Discussion
In the present study we further confirmed our hypothesis
that ACTH lowering apoB containing lipoproteins in
humans mainly via the inhibition of hepatic apoB synthe-
sis but not influence cellular lipid synthesis, which is
compatible to our recent discovery that lipids was han-
dled just as efficiently regardless of the reduced apoB
secretion in response to ACTH administration, suggest-
ing that fewer but more lipid rich lipoproteins are synthe-
sised from the small intestine during ACTH influence
[10].
We have previously reported that ACTH strongly
reduce apoB synthesis and secretion, with almost no fur-
ther accumulation at 48 hrs [11]. This was also seen with
secreted lipids in this case, especially with prelabel
design, suggesting that lipids and lipoproteins may be
subject to recirculation [17]. We have not examined the
catabolism of nascent lipoproteins, and the possibility of
variation in the reuptake of nascent lipids and lipopro-
teins cannot be ruled out, however we don't think this
mechanism can explain the results seen in this study
because ACTH do not affect LDL-receptor mediated
uptake or mRNA levels of LDL-receptor and scavenger
receptor BI receptor [11]. Further, cells almost reach con-
fluence at 48 hrs of lipid accumulating and thus, several
aspects of lipid metabolism may have been altered
[18,19]. At neither 24 nor 48 hrs did ACTH influenced
the cellular lipid pool or lipids secreted in HepG2 cells.
Nor was any affect of ACTH on lipid output seen at ear-
lier time points (4 or 16 hrs). Oleic acid was used in the
experimental medium due to its ability to stimulate apoB
secretion in HepG2 cells by inhibit intracellular apoB
degradation [12]. Previously we have showed that oleic
acid increased the level of apoB secreted 3-fold in HepG2
cells, however it could not reverse the reduced apoB
secretion in response to ACTH [11]. Supplementation of
fatty acids stimulates lipid synthesis, in particular triglyc-
erides, though differences in design, such as time and
source of fatty acid, yield somewhat different results
[20,21]. The results we saw in response to oleic acid in
this study resembles that of others with increased intrac-
ellular triglycerides and greater secretion of cholesterol to
cholesteryl ester among other things [16,22,23]. Whether
oleic acid was present or absent in the experimental
Figure 3 Contents of labelled lipids in cells and media with HSA or HSA-oleic acid. HepG2 cells prelabelled with [14C]acetate or [3H]glycerol was 
incubated with ACTH (200 pM Synecthen) in 0,4 mM Oleic acid bound to HSA (standard conditions) or in only 0,5% HSA. Labelled cholesterol and 
cholesteryl ester and triglyceride and phospholipid, respectively, were evaluated after 24 hrs in cells (A) and media (B). Data represent mean ± SD (N 
= 4-6).
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medium however did not alter the output of labelled lip-
ids in response to ACTH in HepG2 cells in this study.
The fact that secretion of de novo synthesised lipids
was not restrained in parallel with reduced apoB output
in HepG2 cells in response to ACTH has also bee seen in
the human small intestine in vivo [10]. Although these
systems of lipoprotein production may be different the
secretory pathway for triglyceride rich lipoproteins in
liver and intestine share several characteristics [24-26].
Preliminary results in undifferentiated cultured endothe-
lial cells, Caco2, also support that ACTH do not influence
lipid synthesis or secretion directly, but needs to be com-
plemented with studies in polarized cells since they dis-
play typical endothelial cell characteristics [27,28]. To
further study the size and ratio of lipids per apoB of
secreted lipoproteins in response to ACTH both in vivo
and in vitro is of interest and such studies are initiated.
W e  k n o w  A C T H  a d m i n i s t r a t i o n  i n  h u m a n s  l o w e r s
plasma lipids i.e. cholesterol, phospholipids and triglycer-
ides. The hypolipidemic effect includes all apoB-contain-
ing lipoproteins, i.e. LDL, VLDL and the atherogenic
lipoprotein (a). Generally this can be due to a decreased
synthesis or an increased removal of lipoproteins. In
HepG2 cells we have demonstrated that ACTH do not
influence LDL receptor activity or synthesis, thus do not
support an increased elimination of lipoproteins from the
liver. Further, we have concluded that catabolism of
apoB48 containing chylomicrons was not enhanced by
ACTH in a human postprandial study. All this suggests
that catabolism of apoB containing lipoproteins is not the
primary way for ACTH to lower plasma lipids. The find-
ing that ACTH selectively suppress apoB mRNA levels
and secretion in HepG2 cells is of great interest and sup-
ported by the findings in this study, of no influence on
lipid synthesis or secretion, suggests that ACTH primar-
ily act by reducing apoB output, that is the number of
lipoproteins, consequently lowering plasma lipids in
humans by secondary mechanisms. Studies to gain better
understanding of mechanisms by which ACTH actually
lowers plasma lipids may have clinical interest since we,
to the best of our knowledge, postulate that ACTH lowers
plasma lipids by different mechanisms compared to con-
ventional lipid-lowering agents.
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